logo
  

Brocade Announces Pricing Of $500 Mln Convertible Senior Notes Offering Due 2020

Brocade (BRCD) announced the pricing of $500 million principal amount of 1.375% Convertible Senior Notes due 2020 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Brocade said it has also granted the initial purchasers for the offering an option to purchase up to an additional $75 million principal amount of Notes from Brocade solely to cover over-allotments, if any. The sale of the Notes is expected to close on January 14, 2015, subject to customary closing conditions.

Brocade estimates that the proceeds from this offering will be about $490.4 million or $564.1 million if the initial purchasers exercise their over-allotment option in full, after deducting fees and estimated expenses.

The company said it expects to use approximately $30.4 million of the net proceeds of the offering to pay the cost of the convertible note hedge transactions. In addition, Brocade expects to use about $48.9 million of the net proceeds from the offering to repurchase shares of Brocade's common stock concurrently with the pricing of the offering in privately negotiated transactions effected through one of the initial purchasers or its affiliate as Brocade's agent.

Brocade intends to use the remainder of the net proceeds to redeem all of Brocade's outstanding 6.875% senior secured notes due 2020 and for general corporate purposes, including potential acquisitions and other business development activities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT